BlackRock is rapidly widening its South Korean equity exposure, filing 34 new or revised bulk holding disclosures in less than eight months this year, up from six in all of last year, with 31 showing larger positions. Through BlackRock Fund Advisors, it crossed or increased 5% stakes in eight companies this month alone, including HLB, Yuhan Corporation, Alteogen, Naver, Kakao, DB Insurance, Hyundai Engineering & Construction and HD Hyundai Electric, even as local retail money crowded into leveraged semiconductor ETFs. The firm was especially active in biotech, lifting HLB to 7.15% after the company received a third Complete Response Letter from the FDA (U.S. drug regulator), taking Alteogen to 5.03% after a 31.3% share-price drop, and raising Yuhan Corporation to 6.50% as investors watch global sales of Leclaza. Analysts said the moves signal growing foreign institutional interest in undervalued South Korean blue chips and in the country's pharmaceutical, biotech, AI and infrastructure themes, although some cautioned that BlackRock's scale in passive management makes it hard to treat each disclosure as a direct active-buy call. As of the end of June, BlackRock held 5% or more in 19 listed South Korean companies, up by 12 from a year earlier.